Ninety-nine breast cancer patients were enrolled in dose expansion cohorts: 50 patients with HER2-positive MBC, 32 patients with HER2-low hormone-receptor positive disease and 17 patients with HER2-low triple negative MBC [44]. This evidence concerns the gene ERBB2 and breast cancer.